Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?
Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer therapy for solid tumors that results in increased bleeding risk and chemotherapy dose reductions, treatment delays, and agent discontinuation. Unlike other chemotherapy-induced cytopenias, CIT remains without any license...
Saved in:
| Main Author: | Hanny Al-Samkari |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Research and Practice in Thrombosis and Haemostasis |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2475037925003048 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia
by: S. G. Zakharov, et al.
Published: (2024-04-01) -
A multicenter mixed-methods study on the effects of intermittent fasting in patients with immune thrombocytopenia receiving thrombopoietin receptor agonists
by: Mohamed A. Yassin, et al.
Published: (2025-02-01) -
Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia
by: Paschalis Evangelidis, et al.
Published: (2025-01-01) -
Results of long-term treatment with thrombopoietin receptor agonists of resistant primary immune thrombocytopenia
by: O. Yu. Vinogradova, et al.
Published: (2024-12-01) -
Correction of Thrombocytopenia with Thrombopoietin Receptor Agonists in Patients with Liver Cirrhosis Before Elective Surgery or Invasive Procedures
by: T. A. Deeva, et al.
Published: (2025-02-01)